CMR Surgical has secured over $200 million in funding to expand the accessibility of the Versius Surgical System in the U.S. and globally.
The Versius Surgical Robotic System has been used in over 30,000 cases across 30 countries, offering clear clinical benefits for minimal-access surgery.
CMR Surgical aims to capitalize on market expansion opportunities, particularly in the U.S., with Versius offering a transformative solution for surgical teams.
Versius is a portable, modular robotic system designed to enhance surgery precision and efficiency, with biomimicking features for optimal outcomes.
The system integrates 3D HD vision, adaptive instrument control, and ergonomic features for improved surgical performance and reduced fatigue.
Versius supports continuous learning through data capture and digital tools, enhancing surgical care and offering insights for better outcomes.
CMR Surgical's Versius is increasingly adopted in various surgical specialties, positioning it as a leading soft-tissue surgical robot globally.
The company is conducting clinical trials to further demonstrate Versius's capabilities, including pediatric surgery and transoral robotic surgery applications.
CMR Surgical's successful funding round includes participation from existing major investors and Trinity Capital, aiming to drive rapid commercial expansion and innovation.
Lord Vallance lauds the funding round as a testament to the potential of surgical robotics, with CMR focused on advancing global surgical care with Versius.